-
Je něco špatně v tomto záznamu ?
Administration of mucolytic solution before upper endoscopy - double-blind, monocentric, randomized study
M. Stepan, P. Falt, B. Pipek, P. Fojtik, M. Hanousek, M. Hill, O. Urban
Jazyk angličtina Země Česko
Typ dokumentu randomizované kontrolované studie, časopisecké články
NLK
Directory of Open Access Journals
od 2001
Free Medical Journals
od 1998
Medline Complete (EBSCOhost)
od 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
PubMed
34158672
DOI
10.5507/bp.2021.038
Knihovny.cz E-zdroje
- MeSH
- acetylcystein MeSH
- dvojitá slepá metoda MeSH
- expektorancia * MeSH
- gastrointestinální endoskopie * MeSH
- gastroskopie MeSH
- lidé MeSH
- voda MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- randomizované kontrolované studie MeSH
AIMS: Sufficient visibility of the mucosa during upper endoscopy is crucial for successful diagnosis, especially for early neoplastic lesions. Data documenting the effect of administration of mucolytic solution prior to gastroscopy in order to improve mucosal visibility are limited in Europe. The aim of the study was to assess the score of mucosal visibility in the upper gastrointestinal tract after administration of the mucolytic solution defined by us. PATIENTS AND METHODS: This is a monocentric, double-blind, randomized study involving 134 patients indicated for diagnostic upper endoscopy. Patients were randomly assigned to one of three arms, with mucolytic solution (100 mL water + 400 mg N-acetylcysteine + 20 mg simethicone), without the solution , and with 100 mL pure water. During the examination, 11 photographs were taken in defined areas. The visibility score was given by the sum of the score 0-5 from 5 defined localities evaluated by a blinded endoscopist and subsequently by two blinded endoscopists. Other parameters monitored were examination time and a semiquantitative evaluation of residual gastric fluid. RESULTS: The basic characteristics of the group (sex, age, indications for examination) were comparable between arms. The visibility score was similar in all arms - 17.4 ± 1.9 vs. 17.0 ± 2.0 vs. 17.6 ± 1.8 (P=0.32). The examination time and the amount of residual fluid in the stomach were comparable in all arms. CONCLUSIONS: Administration of the mucolytic solution in our study did not increase the mucosal visibility score in the esophagus, stomach and duodenum. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02967094.
Digestive Diseases Center Vitkovice Hospital Ostrava Czech Republic
Faculty of Medicine University of Ostrava Ostrava Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23002216
- 003
- CZ-PrNML
- 005
- 20230517134549.0
- 007
- ta
- 008
- 230406s2023 xr a f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2021.038 $2 doi
- 035 __
- $a (PubMed)34158672
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Štěpán, Michal, $u Digestive Diseases Center, Vitkovice Hospital, Ostrava, Czech Republic $u Department of Internal Medicine II - Gastroenterology and Hepatology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $d 1984- $7 xx0224386
- 245 10
- $a Administration of mucolytic solution before upper endoscopy - double-blind, monocentric, randomized study / $c M. Stepan, P. Falt, B. Pipek, P. Fojtik, M. Hanousek, M. Hill, O. Urban
- 520 9_
- $a AIMS: Sufficient visibility of the mucosa during upper endoscopy is crucial for successful diagnosis, especially for early neoplastic lesions. Data documenting the effect of administration of mucolytic solution prior to gastroscopy in order to improve mucosal visibility are limited in Europe. The aim of the study was to assess the score of mucosal visibility in the upper gastrointestinal tract after administration of the mucolytic solution defined by us. PATIENTS AND METHODS: This is a monocentric, double-blind, randomized study involving 134 patients indicated for diagnostic upper endoscopy. Patients were randomly assigned to one of three arms, with mucolytic solution (100 mL water + 400 mg N-acetylcysteine + 20 mg simethicone), without the solution , and with 100 mL pure water. During the examination, 11 photographs were taken in defined areas. The visibility score was given by the sum of the score 0-5 from 5 defined localities evaluated by a blinded endoscopist and subsequently by two blinded endoscopists. Other parameters monitored were examination time and a semiquantitative evaluation of residual gastric fluid. RESULTS: The basic characteristics of the group (sex, age, indications for examination) were comparable between arms. The visibility score was similar in all arms - 17.4 ± 1.9 vs. 17.0 ± 2.0 vs. 17.6 ± 1.8 (P=0.32). The examination time and the amount of residual fluid in the stomach were comparable in all arms. CONCLUSIONS: Administration of the mucolytic solution in our study did not increase the mucosal visibility score in the esophagus, stomach and duodenum. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02967094.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a expektorancia $7 D005100
- 650 12
- $a gastrointestinální endoskopie $7 D016099
- 650 _2
- $a acetylcystein $7 D000111
- 650 _2
- $a gastroskopie $7 D005773
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a voda $7 D014867
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Falt, Přemysl, $u Department of Internal Medicine II - Gastroenterology and Hepatology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $d 1981- $7 xx0149631
- 700 1_
- $a Pipek, Barbora $u Digestive Diseases Center, Vitkovice Hospital, Ostrava, Czech Republic $u Department of Internal Medicine II - Gastroenterology and Hepatology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $7 xx0224384
- 700 1_
- $a Fojtík, Petr $u Digestive Diseases Center, Vitkovice Hospital, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $7 xx0105601
- 700 1_
- $a Hanousek, Martin $u Digestive Diseases Center, Vitkovice Hospital, Ostrava, Czech Republic $7 xx0258702
- 700 1_
- $a Hill, Martin, $u Institute of Endocrinology, Prague, Czech Republic $d 1962- $7 mzk2005304431
- 700 1_
- $a Urban, Ondřej, $u Department of Internal Medicine II - Gastroenterology and Hepatology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $d 1965- $7 stk2008428564
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 167, č. 1 (2023), s. 69-73
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34158672 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y p $z 0
- 990 __
- $a 20230406 $b ABA008
- 991 __
- $a 20230517134544 $b ABA008
- 999 __
- $a ok $b bmc $g 1933544 $s 1188422
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 167 $c 1 $d 69-73 $e 20210622 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK198 $a Pubmed-20230406